Literature DB >> 28386763

Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease.

Nurullah Akkoç1, Handan Yarkan2, Gökçe Kenar2, Muhammad A Khan3.   

Abstract

PURPOSE OF REVIEW: We review our current knowledge about the clinical features of patients with ankylosing spondylitis (AS) who possess HLA-B*27 versus those who lack this gene. RECENT
FINDINGS: ERAP1 association is present only in HLA-B*27+ patients, but other genetic associations are similar between the two groups. A genetic study supports the existence of an HLA-B27-independent common link between gut inflammation and AS. It is unusual to observe familial occurrence of primary AS among families of northern European extraction that show no segregation of HLA-B*27, psoriasis, or IBD. Although there are many similarities among AS patients possessing HLA-B*27 versus those lacking this gene, the former group has a younger age of onset, a shorter delay in diagnosis, a better clinical response to tumor necrosis factor inhibitors, a greater familial occurrence, a greater risk for occurrence of acute anterior uveitis, and a lower risk for occurrence of psoriasis and IBD. ERAP1 association is present only in HLA-B*27+ patients, but other genetic associations are similar between the two groups. It is unusual to observe occurrence of primary AS among families of northern European extraction that show no segregation of HLA-B*27, IBD, or psoriasis. A recent genetic study supports the existence of an HLA-B*27-independent common link between gut inflammation and AS.

Entities:  

Keywords:  Ankylosing spondylitis; Clinical features; ERAP1; Familial occurrence; Genetic susceptibility; HLA-B*27; HLA-B27; Inflammatory bowel disease; Psoriasis; Spondyloarthritis; Uveitis

Mesh:

Substances:

Year:  2017        PMID: 28386763     DOI: 10.1007/s11926-017-0654-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  84 in total

1.  Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis.

Authors:  M A Brown; S H Laval; S Brophy; A Calin
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.

Authors:  Jürgen Braun; Martin Rudwaleit; Sonja Kary; Martina Kron; Robert L Wong; Hartmut Kupper
Journal:  Rheumatology (Oxford)       Date:  2010-05-06       Impact factor: 7.580

3.  High association of an HL-A antigen, W27, with ankylosing spondylitis.

Authors:  L Schlosstein; P I Terasaki; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

4.  Homozygosity for HLA-B27. Impact on rheumatic disease expression in two families.

Authors:  F C Arnett; B Z Schacter; M C Hochberg; S H Hsu; W B Bias
Journal:  Arthritis Rheum       Date:  1977-04

5.  Familial versus sporadic ankylosing spondylitis. Two different diseases?

Authors:  A Calin; L G Kennedy; L Edmunds; R Will
Journal:  Arthritis Rheum       Date:  1993-05

6.  The influence of HL-A B27 on the clinical picture of ankylosing spondylitis.

Authors:  M Nahir; Y Scharf; R Brik; Y Scharf; O Gidoni
Journal:  Rheumatol Rehabil       Date:  1979-02

7.  The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients.

Authors:  Maxime Dougados; Maria-Antonietta d'Agostino; Joëlle Benessiano; Francis Berenbaum; Maxime Breban; Pascal Claudepierre; Bernard Combe; Patricia Dargent-Molina; Jean-Pierre Daurès; Bruno Fautrel; Antoine Feydy; Philippe Goupille; Véronique Leblanc; Isabelle Logeart; Thao Pham; Pascal Richette; Christian Roux; Martin Rudwaleit; Alain Saraux; Jean-Marc Treluyer; Désirée van der Heijde; Daniel Wendling
Journal:  Joint Bone Spine       Date:  2011-03-31       Impact factor: 4.929

8.  Determinants of early radiographic progression in ankylosing spondylitis.

Authors:  Pamir Atagunduz; Sibel Zehra Aydin; Cengiz Bahadir; Burak Erer; Haner Direskeneli
Journal:  J Rheumatol       Date:  2010-09-15       Impact factor: 4.666

9.  Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis.

Authors:  R D Armstrong; G S Panayi; K I Welsh
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

10.  Epidemiological comparison of clinical manifestations according to HLA-B*27 carrier status of Chinese ankylosing spondylitis patients.

Authors:  M Yang; M Xu; X Pan; Z Hu; Q Li; Y Wei; Y Zhang; J Rong; J Zhai; P He; S Hu; H Song; H Wu; F Zhan; S Liu; G Gao; Z Liu; Y Li; L Shen; A Huang; Z Lin; Z Liao; S Cao; Q Wei; Q Li; Q Lv; J Qi; T Li; O Jin; Y Pan; J Gu
Journal:  Tissue Antigens       Date:  2013-11
View more
  14 in total

1.  A proposed HLA-B*27 screening method for ankylosing spondylitis detection based on tag-single nucleotide polymorphisms: a preliminary study.

Authors:  Gabriela Angélica Martínez-Nava; Yessica Zamudio-Cuevas; Ninoska Aleida Terrazas-Ontiveros; Karina Martínez-Flores; Rolando Espinosa-Morales; Fernando Mijares-Díaz; Shaila Monserrat Juárez-Barreto; Carlos Lozada-Pérez; Margarita Valdés-Flores; Roberto Sánchez-Sánchez; Alberto Hidalgo-Bravo; Javier Fernández-Torres
Journal:  Mol Biol Rep       Date:  2021-10-13       Impact factor: 2.316

2.  The interplay between HLA-B and NLRP3 polymorphisms may be associated with the genetic susceptibility of gout.

Authors:  Javier Fernández-Torres; Gabriela Angélica Martínez-Nava; Karina Martínez-Flores; Roberto Sánchez-Sánchez; Luis J Jara; Yessica Zamudio-Cuevas
Journal:  Mol Biol Rep       Date:  2022-09-03       Impact factor: 2.742

3.  Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis.

Authors:  Trevor Persaud; Richard Morgan; Hein Linn Thant; Francis J DeAsis; Felix Ferre; Jose Diaz
Journal:  Am J Case Rep       Date:  2022-07-01

4.  Musculoskeletal Clinical and Imaging Manifestations in Inflammatory Bowel Diseases.

Authors:  Mihaela Ionela Sarbu; Nicolae Sarbu
Journal:  Open Med (Wars)       Date:  2019-02-20

5.  Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?

Authors:  Miranda van Lunteren; Désirée van der Heijde; Alexandre Sepriano; Inger J Berg; Maxime Dougados; Laure Gossec; Lennart Jacobsson; Roberta Ramonda; Martin Rudwaleit; Joachim Sieper; Robert Landewé; Floris A van Gaalen
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

6.  Ankylosing Spondylitis: A Trade Off of HLA-B27, ERAP, and Pathogen Interconnections? Focus on Sardinia.

Authors:  Fabiana Paladini; Maria Teresa Fiorillo; Valentina Tedeschi; Alberto Cauli; Alessandro Mathieu; Rosa Sorrentino
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

7.  Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review.

Authors:  Diena Davide; Priora Marta; Barreca Antonella; Parisi Simone; Colla Loredana; Biancone Luigi; Fusaro Enrico
Journal:  Clin Med Insights Case Rep       Date:  2020-11-20

8.  Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database.

Authors:  Marta Arévalo; Jordi Gratacós Masmitjà; Mireia Moreno; Joan Calvet; Cristobal Orellana; Desirée Ruiz; Carmen Castro; Pilar Carreto; Marta Larrosa; Eduardo Collantes; Pilar Font
Journal:  Arthritis Res Ther       Date:  2018-10-03       Impact factor: 5.156

9.  A Mechanism Underlying Sex-Associated Differences in Ankylosing Spondylitis: Troponin C2, Fast Skeletal Type (TNNC2) and Calcium Signaling Pathway.

Authors:  Chaojie Yu; Xinli Zhan; Chong Liu; Zide Zhang; Jie Jiang; Guoyong Xu; Jiang Xue
Journal:  Med Sci Monit       Date:  2020-10-14

10.  Optimization of HLA-B*27 ALLELE Genotyping by PCR-SSP.

Authors:  Fernanda Formaggi Lara-Armi; Jeane Eliete Laguila Visentainer; Hugo Vicentin Alves; Marco Antônio Rocha-Loures; Janisleya Silva Ferreira Neves; Cristiane Maria Colli; Quirino Alves de Lima Neto; Ricardo Alberto Moliterno; Ana Maria Sell
Journal:  Clinics (Sao Paulo)       Date:  2020-10-26       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.